文献速递胸部肿瘤

剂量优化以改善有效抗癌药物的可及性

Dose optimisation to improve access to effective cancer medicines.
PubMed 文献 · Lancet Oncol · 2025-01-01

许多世界卫生组织基本药物目录(EML)中的抗癌药物因价格受限,尤其在低中收入国家;一些能改善生存的药物如肺癌免疫检查点抑制剂因批准的剂量和方案超出可负担价格而未纳入EML。监管机构批准的剂量方案可能在强度、频率或持续时间上高于实现有意义生存改善所需。多种证据可用于探索和证明降低强度治疗在获益上的近等效性,包括随机临床试验、剂量探索1期和2期研究以及药代动力学和药效学研究。证明较低剂量或较低强度方案仍保留治疗活性的积极影响包括减少毒性、大幅降价,从而改善成本效果和增加可改善生存的治疗的可及性。

要点

  • 许多EML抗癌药因价格可及性受限,尤其在低中收入国家。
  • 监管批准的剂量方案可能在强度、频率或持续时间上高于必要。
  • 可用随机试验、剂量探索1/2期及药代/药效研究证明减量方案的近等效性。

核心结论

  • 证明较低剂量或较低强度方案仍保留治疗活性可减少毒性并大幅降价,改善成本效果和可及性。

研究设计与样本

  • 本文为针对抗癌药物剂量优化与可及性的综述,检索范围原文未报告。

主要发现

  • 许多EML抗癌药因价格受限,尤其在低中收入国家。
  • 一些能改善生存的药物如肺癌免疫检查点抑制剂因批准剂量和方案超出可负担价格而未纳入EML。
  • 监管批准的剂量方案可能在强度、频率或持续时间上高于实现有意义生存改善所需。

关键数值与推荐

  • 原文未报告具体标准与数值。

临床怎么用

  • 原文建议临床医生和政策制定者在国家和全球层面选择有效药物时,应优先识别在降低剂量和较低强度方案下具有相似结局的方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Access to many cancer medicines on WHO's Essential Medicines List (EML) is restricted because of price, especially in low-income and middle-income countries (LMICs). Other cancer medicines that have been shown to improve survival, such as immune checkpoint inhibitors for lung cancer, are not included on the EML because approved doses and schedules exceed affordable prices in LMICs. Multiple strategies are therefore needed to reduce medicine costs or circumvent these problems, such as optimising doses and schedules. Cancer medicines are approved by regulatory agencies, such as the US Food and Drug Administration and the European Medicines Agency, following rigorous clinical trials. However, these approvals can involve dosing regimens and treatment schedules that, although effective in showing statistically significant benefits in trials, can be higher in intensity, frequency, or duration than is necessary to achieve meaningful improved survival. In clinical practice, these regimens can lead to concerns about balancing optimal therapeutic outcomes with the risk of side-effects, patient quality of life, and long-term health effects. Various types of evidence can, and should, be used to explore and show near-equivalence of beneficial outcomes from reduced-intensity treatments, including randomised clinical trials, dose-finding phase 1 and 2 studies, and pharmacokinetic and pharmacodynamic studies. The positive effects of proving that lower doses or less intensive schedules retain therapeutic activity include reduced toxicity and large price reductions, leading to better cost-effectiveness and greater access to treatments that improve survival. Beyond regulatory approvals, identification of regimens that have similar outcomes with reduced doses and less intense schedules should be a priority for clinicians and policy makers in the selection process to identify effective medicines at national and global levels.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tannock IF, de Vries EGE, Fojo A, et al. Dose optimisation to improve access to effective cancer medicines. Lancet Oncol. 2025. PMID: 40049207. doi:10.1016/S1470-2045(24)00648-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。